29 related articles for article (PubMed ID: 38695547)
1. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S; Nomoto H; Yokoyama H; Suzuki Y; Tsuzuki A; Takahashi K; Miya A; Kameda H; Cho KY; Takeuchi J; Nagai S; Taneda S; Kurihara Y; Nakamura A; Atsumi T;
Diabetes Obes Metab; 2024 Mar; 26(3):961-970. PubMed ID: 38073422
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
3. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
Tan X; Liang Y; Gamble C; King A
Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
Nomoto H; Furusawa S; Nakamura A; Takeuchi J; Nagai S; Yokoyama H; Sakuma I; Taneda S; Kurihara Y; Aoki S; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
BMJ Open; 2022 May; 12(5):e056885. PubMed ID: 35584872
[TBL] [Abstract][Full Text] [Related]
5. Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K; Sugawara M;
Diabetes Ther; 2024 Jun; 15(6):1403-1416. PubMed ID: 38653904
[TBL] [Abstract][Full Text] [Related]
6. Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
Nomoto H; Furusawa S; Yokoyama H; Suzuki Y; Izumihara R; Oe Y; Takahashi K; Miya A; Kameda H; Cho KY; Takeuchi J; Kurihara Y; Nakamura A; Atsumi T
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38695547
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
8. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
9. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.
Goldney J; Sargeant JA; Davies MJ
Diabetologia; 2023 Oct; 66(10):1832-1845. PubMed ID: 37597048
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
[TBL] [Abstract][Full Text] [Related]
12. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]